Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.

It has long been known that antipsychotic drugs (ATP) causes tachycardia, however details such as the differences between ATP are not well known. In recent years, the relationship between the rise in resting heart rate (RHR) and the increased risk of death in the general population has been garnerin...

Full description

Bibliographic Details
Main Authors:	Misuzu Tajiri, Yutaro Suzuki, Takuro Sugai, Nobuto Tsuneyama, Toshiyuki Someya
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6049914?pdf=render

Similar Items

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
by: Nobuto Tsuneyama, et al.
Published: (2016-01-01)

Serum cortisol and insulin-like growth factor 1 levels in major depressive disorder and schizophrenia
by: Hiroshi Arinami, et al.
Published: (2023-01-01)

Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.
by: Norio Sugawara, et al.
Published: (2014-01-01)

High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey.
by: Takuro Sugai, et al.
Published: (2016-01-01)

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey
by: Shin Ono, et al.
Published: (2018-06-01)

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
by: Katagiri Hideaki, et al.
Published: (2013-01-01)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
by: Huimei An, et al.
Published: (2022-06-01)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
by: Mong-Liang Lu, et al.
Published: (2016-01-01)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
by: Jonathan Hindmarsh, et al.
Published: (2020-06-01)

Association Between the Number of Remaining Teeth and Body Mass Index in Japanese Inpatients with Schizophrenia
by: Otake M, et al.
Published: (2022-11-01)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
by: Suzuki H, et al.
Published: (2013-08-01)

Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
by: Lee, C., et al.
Published: (2006)

Topiramate Adjunctive Therapy for Olanzapine Induced Weight Gain in Patients with Schizophrenia
by: Sanjib Pandit, et al.
Published: (2019-08-01)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
by: Wei Zhou, et al.
Published: (2019-03-01)

Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia
by: Habil, H., et al.
Published: (2007)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
by: Ita Fitzgerald, et al.
Published: (2021-09-01)

Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
by: Zhang C, et al.
Published: (2024-03-01)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
by: Rosaria Di Lorenzo, et al.
Published: (2010-09-01)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
by: Chen J, et al.
Published: (2011-11-01)

Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis
by: Dhyuti Gupta, et al.
Published: (2024-01-01)

Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H
by: Yi Zhang, et al.
Published: (2023-07-01)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
by: Osuntokun Olawale, et al.
Published: (2011-05-01)

Does resting heart rate measured by the physician reflect the patient’s true resting heart rate? White-coat heart rate
by: Benoit Lequeux, et al.
Published: (2018-01-01)

Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study
by: Ahmad Fakhri, et al.
Published: (2016-12-01)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
by: Ye W, et al.
Published: (2011-12-01)

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
by: Lingzhi Liang, et al.
Published: (2022-04-01)

Effect of Haloperidol and Olanzapine on Hippocampal Cells’ Proliferation in Animal Model of Schizophrenia
by: Jana Osacka, et al.
Published: (2022-07-01)

High-dose olanzapine in treatment-resistant schizophrenia: a systematic review
by: Louisa Gannon, et al.
Published: (2023-05-01)

Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs
by: Giorgio Mariani, et al.
Published: (2006-09-01)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
by: Citrome L, et al.
Published: (2019-09-01)

Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia
by: Dutina Aleksandra, et al.
Published: (2019-01-01)

Treatment progress of weight gain and abnormal lipid metabolism in patients with schizophrenia caused by clozapine and olanzapine
by: Kang Li, et al.
Published: (2021-04-01)

Effects of long-term therapy with quetiapine and olanzapine on parameters of immunity and cytokine levels in patients with schizophrenia
by: O. Lobacheva, et al.
Published: (2021-04-01)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
by: Lei Zhao, et al.
Published: (2023-08-01)

Effects of varenicline on the serum levels of olanzapine in male patients with Schizophrenia: a randomized controlled trial
by: Mengling Deng, et al.
Published: (2023-05-01)

Post-injection syndrome and olanzapine long-acting injection in patients with schizophrenia: A case series
by: Saheli Dey, et al.
Published: (2022-12-01)

Folic acid, vitamin B12 and homocysteine levels following olanzapine administration in schizophrenia patients
by: Fahmida Hasnat, et al.
Published: (2018-03-01)

Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia
by: Maria-Ioanna Stefanou, et al.
Published: (2020-04-01)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
by: &Uuml;nsal C, et al.
Published: (2013-10-01)

The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment
by: Tzu-Hua Wu, et al.
Published: (2021-08-01)